Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide: a case report
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1752-1947
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Gastrointestinal relapse of multiple myeloma and sustained response to lenalidomide: a case report ; volume:5 ; number:1 ; day:19 ; month:3 ; year:2011 ; pages:1-3 ; date:12.2011
Journal of medical case reports ; 5, Heft 1 (19.3.2011), 1-3, 12.2011
- Creator
-
Benusiglio, Patrick R.
- Contributor
-
McKee, Thomas A.
Montet, Xavier
Dumonceau, Jean-Marc
Favet, Laurence
George, Anne-Claude
Dietrich, Pierre-Yves
SpringerLink (Online service)
- DOI
-
10.1186/1752-1947-5-110
- URN
-
urn:nbn:de:1111-2016071018758
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
- 14.08.2025, 10:46 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Benusiglio, Patrick R.
- McKee, Thomas A.
- Montet, Xavier
- Dumonceau, Jean-Marc
- Favet, Laurence
- George, Anne-Claude
- Dietrich, Pierre-Yves
- SpringerLink (Online service)
Other Objects (12)
Identifying Myeloma Patients at Risk of Lenalidomide or Pomalidomide Resistance at Relapse: A New Opportunity
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE : a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
Identifying Myeloma Patients at Risk of Lenalidomide or Pomalidomide Resistance at Relapse: A New Opportunity
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE : a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5
Lenalidomide vs bortezomib maintenance choice post-autologous hematopoietic cell transplantation for multiple myeloma
Identifying Myeloma Patients at Risk of Lenalidomide or Pomalidomide Resistance at Relapse: A New Opportunity
Pomalidomide, bortezomib, and dexamethasone at first relapse in lenalidomide‐pretreated myeloma: a subanalysis of OPTIMISMM by clinical characteristics
Pomalidomide, bortezomib, and dexamethasone for multiple myeloma previously treated with lenalidomide (OPTIMISMM): outcomes by prior treatment at first relapse
Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE: a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
Rationale and design of the German-Speaking Myeloma Multicenter Group (GMMG) trial ReLApsE : a randomized, open, multicenter phase III trial of lenalidomide/dexamethasone versus lenalidomide/dexamethasone plus subsequent autologous stem cell transplantation and lenalidomide maintenance in patients with relapsed multiple myeloma
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
RUNX proteins desensitize multiple myeloma to lenalidomide via protecting IKZFs from degradation
Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide
Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment
The Cost Impact of Lenalidomide for Newly Diagnosed Multiple Myeloma in the EU5